Edition:
United Kingdom

Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

42.07USD
18 Sep 2018
Change (% chg)

$0.49 (+1.18%)
Prev Close
$41.58
Open
$41.57
Day's High
$42.47
Day's Low
$41.37
Volume
80,112
Avg. Vol
190,773
52-wk High
$50.00
52-wk Low
$24.14

Chart for

About

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the... (more)

Overall

Beta: 1.42
Market Cap(Mil.): $1,019.33
Shares Outstanding(Mil.): 39.22
Dividend: --
Yield (%): --

Financials

  ARNA.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -0.59 -- --
ROI: -13.16 1.78 14.61
ROE: -39.77 3.29 16.33

BRIEF-Arena Pharmaceuticals Reports Q1 Loss Per Share $0.80

* EXPECT TO INITIATE PHASE 3 STUDIES FOR RALINEPAG IN PULMONARY ARTERIAL HYPERTENSION IN SECOND HALF OF 2018

08 May 2018

BRIEF-Arena Pharmaceuticals To Release Q1 Financial Results And Provide Corporate Update On Tuesday, May 8

* ARENA PHARMACEUTICALS TO RELEASE FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE ON TUESDAY, MAY 8 Source text for Eikon: Further company coverage:

02 May 2018

BRIEF-Arena Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

* ARENA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

21 Mar 2018

BRIEF-Arena Pharmaceuticals To Offer 7.5 Mln Shares Of Its Common Stock In An Underwritten Public Offering

* ARENA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

20 Mar 2018

Arena Pharma's bowel disease drug meets study goal, shares surge

Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study, sending its shares up 24 percent.

19 Mar 2018

UPDATE 1-Arena Pharma's bowel disease drug meets study goal, shares surge

March 19 Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study, sending its shares up 24 percent.

19 Mar 2018

Competitors

Earnings vs. Estimates